GlassScriptPhysician profile
Arash Foroughi
NPI 1710113493
$5,072.86
in general payments reported to CMS, 2019-2025
39 companies · $417 in 2025
The $417 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,546 · 2020: $340 · 2021: $737 · 2022: $855 · 2023: $633 · 2024: $544 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550 · Education: $43.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.29 |
| Education | $43.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $671.49 | 2019-2025 | Fintepla, Briviact |
| Livanova USA, INC. | $576.57 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $379.30 | 2019-2021 | |
| Eisai INC. | $343.29 | 2019-2023 | |
| Sk Life Science, INC. | $336.71 | 2021-2025 | Xcopri |
| Sunovion Pharmaceuticals INC. | $315.59 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $227.63 | 2022-2025 | |
| Abbvie INC. | $224.36 | 2021-2025 | |
| Biogen, INC. | $179.20 | 2019-2024 | Tysabri, Vumerity, Spinraza |
| Amgen INC. | $165.49 | 2019-2022 | |
| Emd Serono, INC. | $160.49 | 2019-2025 | Mavenclad |
| Lundbeck LLC | $141.55 | 2022-2025 | Vyepti |
| Neurelis, INC. | $132.60 | 2020-2025 | Valtoco |
| Genzyme Corporation | $121.02 | 2019-2022 | |
| Lilly USA, LLC | $118.14 | 2019-2024 | Emgality |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arash Foroughi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.